Balyasny Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.1M | Buy |
16,400
+3,400
| +26% | +$3.45M | 0.02% | 816 |
|
|
2025
Q4 | $14M | Sell |
13,000
-3,600
| -22% | -$3.44M | 0.02% | 880 |
|
|
2025
Q3 | $12.7M | Buy |
16,600
+9,800
| +144% | +$7.29M | 0.02% | 933 |
|
|
2025
Q2 | $5.3M | Sell |
6,800
-10,400
| -60% | -$8.08M | 0.01% | 1262 |
|
|
2025
Q1 | $14.2M | Buy |
17,200
+7,700
| +81% | +$6.41M | 0.02% | 741 |
|
|
2024
Q4 | $7.33M | Buy |
9,500
+800
| +9% | +$662K | 0.01% | 1104 |
|
|
2024
Q3 | $7.71M | Buy |
8,700
+6,300
| +263% | +$5.66M | 0.01% | 1071 |
|
|
2024
Q2 | $2.17M | Buy |
2,400
+200
| +9% | +$160K | ﹤0.01% | 1500 |
|
|
2024
Q1 | $1.71M | Sell |
2,200
-7,900
| -78% | -$5.62M | ﹤0.01% | 1586 |
|
|
2023
Q4 | $5.89M | Buy |
10,100
+7,100
| +237% | +$4.14M | 0.01% | 1064 |
|
|
2023
Q3 | $1.61M | Buy |
+3,000
| New | +$1.55M | ﹤0.01% | 1436 |
|
|
2022
Q3 | – | Sell |
-551,500
| Closed | -$179M | – | 3079 |
|
|
2022
Q2 | $179M | Buy |
+551,500
| New | +$166M | 0.58% | 10 |
|
|
2021
Q4 | – | Sell |
-10,000
| Closed | -$2.31M | – | 2452 |
|
|
2021
Q3 | $2.31M | Buy |
10,000
+6,500
| +186% | +$1.6M | 0.01% | 1080 |
|
|
2021
Q2 | $803K | Buy |
+3,500
| New | +$703K | ﹤0.01% | 1383 |
|
|
2021
Q1 | – | Sell |
-557,500
| Closed | -$94.1M | – | 1941 |
|
|
2020
Q4 | $94.1M | Buy |
557,500
+527,500
| +1,758% | +$78.8M | 0.52% | 24 |
|
|
2020
Q3 | $4.44M | Sell |
30,000
-70,000
| -70% | -$10.8M | 0.03% | 645 |
|
|
2020
Q2 | $16.4M | Buy |
+100,000
| New | +$15.3M | 0.14% | 216 |
|
|
2020
Q1 | – | Sell |
-50,000
| Closed | -$6.57M | – | 1355 |
|
|
2019
Q4 | $6.57M | Buy |
+50,000
| New | +$5.8M | 0.04% | 531 |
|
|
2018
Q3 | – | Sell |
-215,000
| Closed | -$18.3M | – | 1876 |
|
|
2018
Q2 | $18.3M | Sell |
215,000
-122,500
| -36% | -$10.1M | 0.08% | 334 |
|
|
2018
Q1 | $26.1M | Buy |
+337,500
| New | +$27.2M | 0.11% | 256 |
|
|
2017
Q1 | – | Sell |
-1,220,600
| Closed | -$89.8M | – | 1698 |
|
|
2016
Q4 | $89.8M | Buy |
1,220,600
+1,022,724
| +517% | +$76.2M | 0.48% | 27 |
|
|
2016
Q3 | $438K | Buy |
197,876
+147,876
| +296% | +$11.8M | ﹤0.01% | 762 |
|
|
2016
Q2 | $3.94M | Sell |
50,000
-350,000
| -88% | -$26.3M | 0.03% | 560 |
|
|
2016
Q1 | $28.8M | Buy |
+400,000
| New | +$30.3M | 0.17% | 182 |
|
|
2015
Q3 | – | Sell |
-250,000
| Closed | -$20.9M | – | 1280 |
|
|
2015
Q2 | $20.9M | Buy |
+250,000
| New | +$19M | 0.13% | 207 |
|
|
2013
Q4 | – | Sell |
-50,000
| Closed | -$3.6M | – | 570 |
|
|
2013
Q3 | $3.6M | Buy |
+50,000
| New | +$2.62M | 0.05% | 393 |
|
Other funds holding LLY
VCM
VPM
Balyasny Asset Management's LLY Position: Q1 2026 in Review
Balyasny Asset Management reduced its Eli Lilly (LLY) stake by 86% in Q1 2026, selling an estimated $111M and leaving 17,835 shares worth $16.4M. The position accounts for 0.02% of the portfolio, ranked #778.
Balyasny Asset Management first reported a position in LLY in Q4 2014 and has held it in 39 quarters since. The position peaked at $390M in Q2 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Balyasny Asset Management held 17,835 shares of Eli Lilly worth $16.4M as of Q1 2026.
- Balyasny Asset Management sold 109,173 Eli Lilly shares in Q1 2026, an estimated $111M.
- Eli Lilly made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #778 holding.
- Balyasny Asset Management first reported a position in Eli Lilly in Q4 2014 and has held it in 39 quarters since.
- Balyasny Asset Management's Eli Lilly position peaked at $390M in Q2 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.